Advertisement

Topics

J&J Arthritis Drug Sirukumab Raises Safety Concerns -FDA Staff

12:25 EDT 1 Aug 2017 | Medscape

There were more deaths in patients taking Johnson and Johnson's experimental rheumatoid arthritis drug sirukumab than among those taking a placebo, staff reviewers for the U.S. Food and Drug Administration said in a report published Monday.
Reuters Health Information

Original Article: J&J Arthritis Drug Sirukumab Raises Safety Concerns -FDA Staff

NEXT ARTICLE

More From BioPortfolio on "J&J Arthritis Drug Sirukumab Raises Safety Concerns -FDA Staff"

Quick Search
Advertisement
 

Relevant Topic

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...